BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, Huang RJ, Lian MJ, Lian WL, Xu QH, Sun YQ, Cai LS. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg 2025; 17(6): 106361 [PMID: 40584486 DOI: 10.4240/wjgs.v17.i6.106361]
URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106361.htm
Number Citing Articles
1
Yu-Qing Cao, Meng Song, Xiang-Ming Huang, Fei-Yu Wang, Ying Peng, Jie Cao, Ai-Guo Cao, Xin-En Huang. Sintilimab Plus Nanoparticle Polymeric Micellar Paclitaxel and S-1 as First-Line Treatment in HER2-Negative Advanced Gastric Cancer: A Real-World StudyJournal of Gastrointestinal Cancer 2026; 57(1) doi: 10.1007/s12029-025-01390-x
2
Lorrany Larisse Costa Rodrigues, Rebeca Ferreira de Souza, Bianca Gonzaga Freitas, Leticia Gomes, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Filipe Luis Vasconcelos Visani, Otávio Al-Alam. Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-AnalysisJournal of Gastrointestinal Cancer 2026; 57(1) doi: 10.1007/s12029-026-01418-w
3
Margaret Mekuriya Bassaye, Zou Jijian, Zhou Li, Shuai Han. Long-term durable response to Sintilimab therapy in synchronous lung squamous cell carcinoma and gastric adenocarcinoma: a rare case reportFrontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1679799